Skip to main content

Asterand Lands $5.4M NCI Contract

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asterand said today that it has won a contract from the National Institutes of Health valued at up to $24.3 million to support The Cancer Genome Atlas program.

Under the National Cancer Institute contract, which gives Asterand $5.4 million over a 17-month period and includes an option for renewal, the firm will supply clinically annotated human biospecimens to NCI for use in TCGA projects.

Asterand provides human tissue and research services, and it manages a network of more than 100 collaborative donor institutions and has a repository of several hundred thousand specimens.

"TCGA will revolutionize the molecular understanding of cancer," Asterand CEO Martyn Coombs said in a statement. "This project emphasizes the significant impact of well characterized and high quality human specimens on modern biomedical research."

He added that the NCI contract "plays an important part in our strategy to expand our work with government institutions."

Part of this contract is funded under the America Recovery and Reinvestment Act, Asterand said.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.